Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan – A Case Report
<p>Introduction: The most formidable primary tumor in the central nervous system is glioblastoma multiforme (GBM), distinguished by a median survival duration of just 12 months and recurrence likelihoods above 90% in less than 6 months following therapy. In spite of the implementation of...
Na minha lista:
| Principais autores: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Karger Publishers
2026-01-01
|
| coleção: | Case Reports in Oncology |
| Acesso em linha: | https://karger.com/article/doi/10.1159/000549567 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|